FibroGen (NASDAQ:FGEN) Announces Earnings Results

FibroGen (NASDAQ:FGEN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21, Zacks reports. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the company posted ($0.52) EPS.

FibroGen Stock Up 11.3 %

Shares of NASDAQ FGEN opened at $0.37 on Friday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93. The company has a 50-day moving average of $0.37 and a two-hundred day moving average of $0.72.

Analyst Ratings Changes

Several analysts recently commented on FGEN shares. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday. StockNews.com assumed coverage on FibroGen in a research report on Thursday. They issued a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.